sufentanil (Rx)

  • Print
Brand and Other Names:Sufenta

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

injectable solution: Schedule II

  • 0.05mg/mL
more...

Anesthesia

Induction/intubation: 1-2 mcg/kg IV, THEN 10-50 mcg IV PRN 

General Anesthesia: 8-30 mcg/kg IV, THEN 25-30 mcg IV PRN

Should be administered with 100% O2, with ventilatory support

Dose should be calculated based on ideal body weight

Other Indications & Uses

Low dose: Analgesia in intubation, ventilation (adjunct)

High dose: Primary anesthesia induction & maint

Epidural analgesia (with bupivacaine)

Dosage Forms & Strengths

injectable solution: Schedule II

  • 0.05mg/mL
more...

Anesthesia

<2 years: Safety and efficacy not established

2-12 years: 10-25 mcg/kg IV increments

>12 years: 8-30 mcg/kg IV, THEN 25-30 mcg IV PRN

Anesthesia

Induction/intubation: 1-2 mcg/kg IV, THEN 10-50 mcg IV PRN 

General Anesthesia: 8-30 mcg/kg   IV, THEN 25-30 mcg IV PRN

Should be administered with 100% O2, with ventilatory support

Dose should be calculated based on ideal body weight

Next:

Interactions

Interaction Checker

and sufentanil

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Frequency Not Defined

            Nausea

            Vomiting

            Constipation

            Sweating, flushing, warmness of the face/neck/upper thorax

            Pruritus, urticaria

            Bradycardia

            Dizziness

            Visual disturbances

            Mentalclouding/depression

            Sedation

            Coma

            Euphoria/Dysphoria

            Weakness

            Faintness

            Agitation

            Restlessness

            Nervousness

            Seizures

            Anticholinergic effects (dry mouth, palpitation, tachycardia)

            Respiratory/circulatory depression

            Respiratory arrest, shock, cardiac arrest

            QT-interval prolongation, severe cardiac arrhythmias, cardiac arrest, ST segment elevation, ventricular tachycardia

            Myocardial infarction, angina pectoris, syncope

            Urinary retention, oliguria

            Previous
            Next:

            Warnings

            Contraindications

            Relative: hepatic function impairment

            Cautions

            Bradycardia, compromised cardiac reserve, head injury, hypothyroidism, increased intracranial pressure, intracranial lesions, renal function impairment, respiratory impairment

            Concurrent administration of benzodiazepine or neuromuscular blocker will decrease chest wall rigidity

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: not known if excreted in breast milk

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            May open K+ channels and inhibit Ca++ channels, causing an increase in pain threshold and alteration in pain perception. It also inhibits ascending pain pathways

            Pharmacokinetics

            Half-life: 5-10hr (neonates); 55-139 min (infants and children); 164 min (adults)

            Onset: 1-3 min (IV); 10 min (epidural)

            Duration: 2.3-3.8 hr

            Peak Plasma: 36-43 ng/mL

            Protein Bound: 93% (adults); 79% (neonates)

            Vd: 2.48 L/kg

            Metabolism: hepatic P450 enzyme CYP3A4; (N-dealkylation, O-demethylation)

            Excretion: Urine (primarily)

            Previous
            Next:

            Administration

            IV Compatibilities

            Solution: D5W, NS (5 mg/L)

            Additive: bupivacaine, ropivacaine

            Syringe: atracurium, atropine, dexamethasone, diphenhydramine, haloperidol, hydroxyzine, ketorolac, methotrimeprazine, metoclopramide, midazolam, prochlorperazine, scopolamine

            Y-site: ampho B chol SO4, atropine, bivalirudin, ceftazidime, cisatracurium, dexamethasone, dexmedetomidine, diazepam, diphenhydramine, etomidate, fenoldopam, gatifloxacin, haloperidol, Hextend, hydroxyzine, ketorolac, linezolid, methotrimeprazine, metoclopramide, midazolam, phenobarbital, prochlorperazine, propofol, remifentanil, scopolamine

            IV Incompatibilities

            Solution: NS (20 mg/L)

            Syringe: diazepam, lorazepam, phenobarbital, phenytoin

            Y-site: lorazepam, phenytoin, thiopental

            IV Administration

            Administer by IV injection or epidural injection

            Has also been administered by IM injection or by intermittent IV infusion

            Storage

            Protect from light

            Store at 15-25°C

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous